RecruitingNCT07032103

Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV

A Prospective Study for Patients With Lymphoma at the Samsung Medical Center

Sponsor

Samsung Medical Center

Enrollment

2,000 participants

Start Date

Jun 1, 2022

Study Type

OBSERVATIONAL

Conditions

Lymphoma

Summary

This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.

Eligibility

Plain Language Summary

Simplified for easier understanding

This is a long-term observational study tracking the health outcomes of people diagnosed with lymphoma — a cancer of the immune system — who are receiving chemotherapy with the goal of a cure. **You may be eligible if...** - You have been diagnosed with Hodgkin or non-Hodgkin lymphoma (confirmed by a tissue biopsy) - You are 20 years old or older - You need chemotherapy with a curative goal - You are willing to provide written consent **You may NOT be eligible if...** - You have a myeloid blood cancer (like AML or MDS) - You have multiple myeloma - Your treatment is not intended to be curative Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.